PolarCool sign an agreement with French rugby super club Racing 92

Report this content

The med-tec company PolarCool AB (publ) continues to establish PolarCap® in professional rugby, by signing a strategic agreement with Top14 giant Racing 92.

PolarCool develops and markets the product PolarCap, which alleviates the effects of concussion. The primary users of PolarCap include sports clubs, organizations, and facilities in contact sports such as ice hockey, rugby, football and handball, but also other sports with an increased risk of concussion. PolarCool’s goal is to strengthen its presence in French rugby and the agreement brings strategic value, even if the financial significance of individual agreements are limited.

PolarCool has recently signed a number of important agreements with professional rugby clubs, in both France and the United Kingdom. The company has an ongoing partnership with Top14 club Stade Français and has most recently formed an agreement with English professional club London Irish.

Racing 92 are a French rugby super club, based in Paris, they boast one of the most impressive squads in world rugby and are known as a powerhouse of the modern professional rugby era. As well as national success, the club regularly competes in the European Rugby Champions Cup, finishing as runners-up in 2019/2020.

PolarCool's CEO Erik Andersson comments;

-Continuing to establish PolarCap in the European rugby market is one of the company's primary goals. The Top14 is the leading and financially strongest rugby league in the world making the agreement with Racing 92 an important strategic step forward. The agreement shows increased interest in the PolarCap System from professional rugby clubs in Europe.

 For more information

Erik Andersson –  CEO PolarCool AB (publ)               
+46 - 738 60 57 00                                         
E-mail: erik.andersson@polarcool.se
 

About PolarCool AB (publ)

PolarCool AB (publ) is a medical device company that develops, markets, and sells products for sports medicine. The company focuses on treatment of concussive and sub-concussive brain injury with the portable cooling device PolarCap® System. PolarCool AB (publ) is based in Lund, Sweden, and its shares are listed on Spotlight Stock Market.